

ISO 11616:2017-10 (E)

Health informatics - Identification of medicinal products - Data elements and structures for unique identification and exchange of regulated pharmaceutical product information

Contents		Page
Foreword		v
Introduction		vi
1	Scope	1
2	Normative references	1
3	Terms, definitions and abbreviated terms	2
4	Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	9
5	Requirements	9
5.1	Elements required for the unique identification of pharmaceutical products	9
5.2	Exchange of pharmaceutical product information	10
6	Description of the information modelling principles and practices	10
6.1	General considerations	10
6.2	Conceptual overview diagrams	11
6.3	High-level diagrams	11
6.4	Detailed description diagrams	12
6.4.1	General	12
6.4.2	Relationships between classes	13
6.4.3	Attributes of classes	14
6.4.4	Generalised classes and patterns	14
6.4.5	Translation and language	14
7	Identifying characteristics for the identification of pharmaceutical products	14
7.1	Pharmaceutical product identification strata and levels	14
7.1.1	General	14
7.1.2	PhPID specified substance	15
7.1.3	Pharmaceutical product specified substance identification (PhPID SpSub)	16
7.2	Cardinality	17
7.3	Representation of strength concentration	17
7.4	Pharmaceutical product identifier (PhPID)	18
7.5	Pharmaceutical product substance stratum elements (PhPID_SUB_Lx)	18
7.5.1	Construct of the pharmaceutical product substance stratum	18
7.5.2	Substance set	18
7.5.3	Administrable dose form	19
7.5.4	Unit of presentation	19
7.5.5	Medical device	19
7.6	Pharmaceutical product specified substance stratum elements (PhPID_SpSUB_Lx)	19
7.6.1	Construct of the pharmaceutical product specified substance stratum	19
7.6.2	Specified substance set	20
7.6.3	Administrable dose form	20
7.6.4	Unit of presentation	20
7.6.5	Medical device	20
7.7	Identifying characteristics to express strength	20

7.7.1	Expressing strength	20
7.7.2	Attributes for representation of strength in PhPID stratum elements	21
7.7.3	Representation of strength for a patch	23
8	Relationship between MPID/PCID and PhPID	23
8.1	Concepts required for the unique identification of a Medicinal Product and the association with PhPIDs	23
8.2	Pharmaceutical product identification criteria	25
8.2.1	General considerations	25
8.2.2	Multiple products packaged as a kit and administered as separate Medicinal Products	25
8.2.3	Multiple products packaged as a kit for reconstitution and administered as one Medicinal Product	26
8.2.4	Components of kits which are not packaged together (e.g. radiopharmaceutical kits)	26
8.2.5	Different representations of strength in two or more regions for identical products	26
8.2.6	Representation of PhPID for a patch	27
9	Relationship between IMPID/IPCID and PhPID	27
10	Conceptual model	29
	Bibliography	30